Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$5.63 - $8.27 $497,720 - $731,109
88,405 Added 328.8%
115,292 $780,000
Q2 2023

Aug 14, 2023

BUY
$11.12 - $22.2 $298,983 - $596,891
26,887 New
26,887 $308,000
Q1 2022

May 16, 2022

SELL
$14.54 - $21.5 $296,383 - $438,256
-20,384 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$20.24 - $36.01 $412,572 - $734,027
20,384 New
20,384 $423,000
Q3 2021

Nov 15, 2021

SELL
$26.01 - $38.22 $876,849 - $1.29 Million
-33,712 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$29.97 - $37.17 $36,353 - $45,087
1,213 Added 3.73%
33,712 $1.04 Million
Q1 2021

May 17, 2021

BUY
$29.24 - $42.03 $655,151 - $941,724
22,406 Added 222.0%
32,499 $1.1 Million
Q4 2020

Feb 16, 2021

SELL
$35.35 - $50.67 $948,900 - $1.36 Million
-26,843 Reduced 72.67%
10,093 $365,000
Q3 2020

Nov 16, 2020

BUY
$35.98 - $47.66 $1.33 Million - $1.76 Million
36,936 New
36,936 $1.36 Million
Q2 2020

Aug 14, 2020

SELL
$45.06 - $67.74 $277,344 - $416,939
-6,155 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$40.01 - $73.97 $534,413 - $988,017
-13,357 Reduced 68.46%
6,155 $292,000
Q4 2019

Feb 14, 2020

BUY
$37.13 - $74.62 $158,433 - $318,403
4,267 Added 27.99%
19,512 $1.4 Million
Q3 2019

Nov 14, 2019

SELL
$39.36 - $76.8 $868,084 - $1.69 Million
-22,055 Reduced 59.13%
15,245 $600,000
Q2 2019

Aug 14, 2019

BUY
$52.76 - $82.19 $726,716 - $1.13 Million
13,774 Added 58.55%
37,300 $2.92 Million
Q1 2019

May 15, 2019

BUY
$27.39 - $68.41 $224,817 - $561,509
8,208 Added 53.58%
23,526 $1.4 Million
Q4 2018

Feb 14, 2019

SELL
$22.8 - $33.93 $251,780 - $374,688
-11,043 Reduced 41.89%
15,318 $441,000
Q3 2018

Nov 14, 2018

SELL
$29.75 - $43.08 $1.06 Million - $1.53 Million
-35,556 Reduced 57.43%
26,361 $959,000
Q2 2018

Aug 14, 2018

BUY
$21.96 - $39.94 $526,425 - $957,441
23,972 Added 63.18%
61,917 $2.34 Million
Q1 2018

May 15, 2018

BUY
$17.1 - $26.61 $648,859 - $1.01 Million
37,945 New
37,945 $892,000

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $300M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Squarepoint Ops LLC Portfolio

Follow Squarepoint Ops LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

News

Stay updated on Squarepoint Ops LLC with notifications on news.